Data Insights

BNT-321 by BioNTech for Solid Tumor: Likelihood of Approval

BNT-321 is under clinical development by BioNTech and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-321 in Solid Tumor

Data Insights

BNT-314 by BioNTech for Solid Tumor: Likelihood of Approval

BNT-314 is under clinical development by BioNTech and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-314 in Solid Tumor

Data Insights

DB-1311 by BioNTech for Solid Tumor: Likelihood of Approval

DB-1311 is under clinical development by BioNTech and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - DB-1311 in Solid Tumor

Data Insights

PF-07921186 by BioNTech for Herpes Zoster (Shingles): Likelihood of Approval

PF-07921186 is under clinical development by BioNTech and currently in Phase II for Herpes Zoster (Shingles). According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - PF-07921186 in Herpes Zoster (Shingles)

Data Insights

BNT-113 by BioNTech for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

BNT-113 is under clinical development by BioNTech and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC)....

Likelihood of Approval and Phase Transition Success Rate Model - BNT-113 in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

BNT-113 by BioNTech for Penile Cancer: Likelihood of Approval

BNT-113 is under clinical development by BioNTech and currently in Phase II for Penile Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-113 in Penile Cancer

Data Insights

BNT-113 by BioNTech for Cervical Cancer: Likelihood of Approval

BNT-113 is under clinical development by BioNTech and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-113 in Cervical Cancer

Data Insights

BNT-111 by BioNTech for Melanoma: Likelihood of Approval

BNT-111 is under clinical development by BioNTech and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-111 in Melanoma

Data Insights

BNT-164 by BioNTech for Tuberculosis: Likelihood of Approval

BNT-164 is under clinical development by BioNTech and currently in Phase II for Tuberculosis. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-164 in Tuberculosis

Data Insights

BNT-211 by BioNTech for Esophageal Cancer: Likelihood of Approval

BNT-211 is under clinical development by BioNTech and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-211 in Esophageal Cancer

Data Insights

BNT-166a by BioNTech for Monkeypox: Likelihood of Approval

BNT-166a is under clinical development by BioNTech and currently in Phase II for Monkeypox. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-166a in Monkeypox

Data Insights

BNT-211 by BioNTech for Testicular Cancer: Likelihood of Approval

BNT-211 is under clinical development by BioNTech and currently in Phase II for Testicular Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-211 in Testicular Cancer

Data Insights

BNT-111 by BioNTech for Metastatic Melanoma: Likelihood of Approval

BNT-111 is under clinical development by BioNTech and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-111 in Metastatic Melanoma

Data Insights

BNT-211 by BioNTech for Endometrial Cancer: Likelihood of Approval

BNT-211 is under clinical development by BioNTech and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-211 in Endometrial Cancer

Data Insights

BNT-211 by BioNTech for Sarcomas: Likelihood of Approval

BNT-211 is under clinical development by BioNTech and currently in Phase II for Sarcomas. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-211 in Sarcomas

Data Insights

BNT-211 by BioNTech for Gastric Cancer: Likelihood of Approval

BNT-211 is under clinical development by BioNTech and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-211 in Gastric Cancer

Data Insights

BNT-211 by BioNTech for Ovarian Cancer: Likelihood of Approval

BNT-211 is under clinical development by BioNTech and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-211 in Ovarian Cancer

Data Insights

PF-07921188 by BioNTech for Herpes Zoster (Shingles): Likelihood of Approval

PF-07921188 is under clinical development by BioNTech and currently in Phase II for Herpes Zoster (Shingles). According to GlobalData, Phase...

Data Insights

Acasunlimab by BioNTech for Endometrial Cancer: Likelihood of Approval

Acasunlimab is under clinical development by BioNTech and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II...

Data Insights

BNT-312 by BioNTech for Pancreatic Cancer: Likelihood of Approval

BNT-312 is under clinical development by BioNTech and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II...